Rehman Mahrukh, Shah Maria, Gul Mehak, Shamoon Vanesa, Tariq Muhammad M, Bibi Khansa, Ishola Ahmed O, Manoharan Mmahaletchumy, Anika Nabila N, Bilal Ali
Surgery, S.Tentishev Asian Medical Institute, Kant, KGZ.
Surgery, Liaquat University of Medical and Health Sciences, Hyderabad, PAK.
Cureus. 2025 May 3;17(5):e83418. doi: 10.7759/cureus.83418. eCollection 2025 May.
This systematic review evaluates and compares the long-term survival and recurrence outcomes of liver transplantation (LT) versus liver resection (LR) in patients with hepatocellular carcinoma (HCC) and underlying cirrhosis. A comprehensive search was conducted in accordance with PRISMA guidelines across PubMed, Embase, and the Cochrane Library, yielding 415 articles, of which four high-quality meta-analyses were included based on predefined eligibility criteria. The included studies encompassed tens of thousands of patients and consistently demonstrated that LT offers superior overall survival (OS) and disease-free survival (DFS), along with significantly lower recurrence rates, when compared to LR. Subgroup analyses revealed that the survival advantage of LT is more pronounced in patients within the Milan criteria or those with multifocal disease, while outcomes of LR improved over time, particularly in cases with solitary tumors and structured postoperative surveillance. The review also highlights the influence of geographic disparities, institutional practices, and healthcare resource availability on treatment selection and outcomes. Quality assessment using the AMSTAR 2 tool confirmed that three studies were of high quality with low risk of bias, while one was of moderate quality. These findings support the use of LT as the preferred treatment for eligible patients, while acknowledging LR as a valuable alternative in specific clinical scenarios, particularly where organ availability is limited.
本系统评价评估并比较了肝细胞癌(HCC)合并潜在肝硬化患者肝移植(LT)与肝切除(LR)的长期生存和复发结局。按照PRISMA指南在PubMed、Embase和Cochrane图书馆进行了全面检索,共获得415篇文章,根据预先定义的纳入标准纳入了4项高质量的荟萃分析。纳入的研究涵盖了数万名患者,一致表明与LR相比,LT具有更好的总生存期(OS)和无病生存期(DFS),复发率也显著更低。亚组分析显示,LT的生存优势在符合米兰标准的患者或多灶性疾病患者中更为明显,而LR的结局随时间有所改善,特别是在孤立肿瘤和有结构化术后监测的病例中。该评价还强调了地理差异、机构实践和医疗资源可用性对治疗选择和结局的影响。使用AMSTAR 2工具进行的质量评估证实,3项研究质量高,偏倚风险低,1项研究质量中等。这些发现支持将LT作为符合条件患者的首选治疗方法,同时承认LR在特定临床场景中是一种有价值的替代方法,特别是在器官可用性有限的情况下。